MYBL2 and breast carcinoma: In contrast, small interfering RNA (siRNA)-mediated knockdown of MYBL2 downregulated reporter activity in MCF7 and T47D cells as well as the estrogen receptor–negative breast cancer line Hs578T, revealing that B-Myb might modulate A3B promoter activity in breast cancer cells (Fig. 2B).